Results 201 to 210 of about 510,489 (255)
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan +6 more
wiley +1 more source
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen +7 more
wiley +1 more source
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang +7 more
wiley +1 more source
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang +13 more
wiley +1 more source
Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia +7 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of the American Statistical Association, 2004
Miller has studied the asymptotic efficiency of the nonparametric, Kaplan–Meier survival estimator relative to parametric estimates based on the exponential and Weibull distributions. He concluded that in certain cases, the asymptotic efficiency is low and recommended that analysts give more consideration to parametric estimators, particularly for ...
Rick Chappell, Hui Xie
exaly +4 more sources
Miller has studied the asymptotic efficiency of the nonparametric, Kaplan–Meier survival estimator relative to parametric estimates based on the exponential and Weibull distributions. He concluded that in certain cases, the asymptotic efficiency is low and recommended that analysts give more consideration to parametric estimators, particularly for ...
Rick Chappell, Hui Xie
exaly +4 more sources
The analysis of survival data: the Kaplan–Meier method [PDF]
What is this patient's prognosis regarding graft rejection? Do patients using a particular drug live longer than those not using it? How does this co-morbidity affect access to transplantation? To answer this type of questions one needs to perform survival analysis.
Kitty J Jäger +2 more
exaly +5 more sources
The Jackknife Estimate of a Kaplan-Meier Integral
Biometrika, 1994Summary: We derive an explicit formula for the jackknife estimate of a Kaplan- Meier integral. From this the asymptotic analysis of the jackknifed Kaplan-Meier process becomes straightforward. In a small simulation study it is demonstrated that jackknifing may lead to a considerable reduction of the bias.
Stute, Winfried, Wang, Jane-Ling
openaire +2 more sources
Biometrics, 1983
The asymptotic efficiency of the Kaplan-Meier product-limit estimator, relative to the maximum likelihood estimator of a parametric survival function, is examined under a random-censoring model.
openaire +2 more sources
The asymptotic efficiency of the Kaplan-Meier product-limit estimator, relative to the maximum likelihood estimator of a parametric survival function, is examined under a random-censoring model.
openaire +2 more sources

